SUTRO BIOPHARMA, INC. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-12: Disclosure Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-12: Disclosure Non Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-12: Disclosure Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-12: Disclosure Non Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-12 10-Q | Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-12 10-Q | Non Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-12 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-12 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-05-14 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-14 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-14 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-14 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-04-22 DEF 14A | PEO Total Compensation | Individual: MsChung | 2024-01-01..2024-12-31 | |
| 2026-04-22 DEF 14A | PEO Actually Paid Compensation | Individual: MsChung | 2024-01-01..2024-12-31 | |
| 2026-04-22 DEF 14A | PEO Total Compensation | Individual: MsChung | 2023-01-01..2023-12-31 | |
| 2026-04-22 DEF 14A | PEO Actually Paid Compensation | Individual: MsChung | 2023-01-01..2023-12-31 | |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo; Individual: MsChung | 2025-01-01..2025-12-31 | |
| 2026-04-22 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-22 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | Our equity awards, including stock options, are granted in connection with our yearly compensation cycle and regularly scheduled meetings of our Compensation Committee. Our Compensation Committee does not grant equity awards in anticipation of the release of material non-public information . Similar… | |
| 2026-04-22 DEF 14A | Award Timing How MNPI Considered | 2025-01-01..2025-12-31 | Our Compensation Committee does not grant equity awards in anticipation of the release of material non-public information . | |
| 2026-04-22 DEF 14A | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-22 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-04-22 DEF 14A | Pay versus Performance Table | 2025-01-01..2025-12-31 | PAY VERSUS PERFORMANCE In accordance with rules adopted by the Securities and Exchange Commission pursuant to Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we provide the following disclosure regarding executive compensation for our principal executive offi… | |
| 2026-04-22 DEF 14A | PEO Total Compensation | Individual: MsChung | 2025-01-01..2025-12-31 | $1.58B |
| 2026-04-22 DEF 14A | PEO Actually Paid Compensation | Individual: MsChung | 2025-01-01..2025-12-31 | $1.87B |
| 2026-04-22 DEF 14A | PEO Total Compensation | Individual: MrNewell | 2025-01-01..2025-12-31 | $1.67B |
| 2026-04-22 DEF 14A | PEO Actually Paid Compensation | Individual: MrNewell | 2025-01-01..2025-12-31 | $1.14B |
| 2026-04-22 DEF 14A | PEO Total Compensation | Individual: MrNewell | 2024-01-01..2024-12-31 | $2.33B |
| 2026-04-22 DEF 14A | PEO Actually Paid Compensation | Individual: MrNewell | 2024-01-01..2024-12-31 | $925.01M |
| 2026-04-22 DEF 14A | PEO Total Compensation | Individual: MrNewell | 2023-01-01..2023-12-31 | $2.13B |
| 2026-04-22 DEF 14A | PEO Actually Paid Compensation | Individual: MrNewell | 2023-01-01..2023-12-31 | -$539.43M |
| 2026-04-22 DEF 14A | Named Executive Officers Footnote | 2025-01-01..2025-12-31 | (3) Mr. Newell served as the Company's CEO from January 12, 2009 to March 13, 2025. Values shown relate to Mr. Newell's service as CEO during fiscal years 2025, 2024, and 2023 . (4) The other NEOs in each covered year were as follows: 2025 - Greg Chow, Hanspeter Gerber; 2024 - Edward Albini, Jane Ch… | |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo; Individual: MsChung | 2025-01-01..2025-12-31 | -$412.68M |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo; Individual: MrNewell | 2025-01-01..2025-12-31 | $0.00 |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo; Individual: MsChung | 2025-01-01..2025-12-31 | $834.15M |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo; Individual: MrNewell | 2025-01-01..2025-12-31 | $0.00 |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo; Individual: MsChung | 2025-01-01..2025-12-31 | $81.59M |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo; Individual: MrNewell | 2025-01-01..2025-12-31 | $0.00 |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo; Individual: MsChung | 2025-01-01..2025-12-31 | -$130.63M |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo; Individual: MrNewell | 2025-01-01..2025-12-31 | -$69.78M |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo; Individual: MsChung | 2025-01-01..2025-12-31 | -$79.39M |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo; Individual: MrNewell | 2025-01-01..2025-12-31 | -$87.84M |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo; Individual: MrNewell | 2025-01-01..2025-12-31 | -$375.13M |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$252.75M |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $363.41M |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $8.06M |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$103.52M |
| 2026-04-22 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$18.16M |
| 2026-04-22 DEF 14A | Adjustment To PEO Compensation Footnote | 2025-01-01..2025-12-31 | * All stock option valuations included in "Compensation Actually Paid" values were performed using the Black-Scholes option pricing model in a manner generally consistent with the process used to determine stock option grant date fair values under FASB ASC Topic 718 (refer to our annual re… | |
| 2026-04-22 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2025-01-01..2025-12-31 | The relationship between Compensation Actually Paid (CAP) and the financial performance elements reflected in the above Pay versus Performance tables are described in the below charts: | |
| 2026-04-22 DEF 14A | Compensation Actually Paid Vs Net Income | 2025-01-01..2025-12-31 | ||
| 2026-03-23 10-K | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-23 10-K | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-23 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-23 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-23 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |